Journal Article

Targeting IDH in Low-Grade Glioma

  • Claus E
  • Verhaak R
New England Journal of Medicine (2023) 389(7) 655-659
DOI: 10.1056/nejme2305602
11Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Vorasidenib for Grade 2 Glioma This editorial describes the science behind a trial of vorasidenib, an inhibitor of variant isocitrate dehydrogenase, to treat grade 2 glioma.

Cite

CITATION STYLE

APA

Claus, E. B., & Verhaak, R. G. W. (2023). Targeting IDH in Low-Grade Glioma. New England Journal of Medicine, 389(7), 655–659. https://doi.org/10.1056/nejme2305602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free